Algernon Pharmaceuticals has entered an Investigator-Initiated Clinical Trial Agreement with Yale University to investigate multiple intravenous doses of DMT for the treatment of depression.
For the study, Algernon will provide cGMP DMT and will jointly own intellectual property around the clinical use of DMT arising from the study.
The company will also have the option to negotiate licenses to both IP developed jointly and IP developed solely by Yale, and will receive data from the study, which may assist in its DMT stroke research programme.
The trial’s principal investigator is Deepak Cyril D’Souza, MBBS MD, Professor of Psychiatry and Director of the Schizophrenia Neuropharmacology Research Group at the Yale University School of Medicine, an experienced researcher with DMT and other controlled substances.
D’Souza commented: “The study may enhance our current understanding of the dosing regimen in the subjective effects induced by DMT.”
CEO of Algernon Pharmaceuticals, Christopher J. Moreau, added: “After careful consideration, we chose to support Dr D’Souza’s clinical DMT study and work with Yale University.
“Although the treatment of psychiatric disorders with DMT are not the company’s current focus, we have patents pending on novel forms of DMT which could potentially be used across a broad range of diseases. In addition, we believe the data generated from this study may help inform Algernon’s stroke research programme.
“A rising tide lifts all boats, and we feel a corporate responsibility as well to improve global awareness and support psychedelic medicine research when possible. It is in that spirit that we also chose to become the lead sponsor of Wonderland, the world’s largest conference on psychedelic medicine to be held November 3-5 in Miami.”
The double-blind, placebo-controlled, crossover-controlled study will compare different bolus and constant infusion dosing regimens of DMT in healthy control participants and individuals with depression.
